Lipid Lowering Therapy with Statins in Patients with Heterozygous Familial Hypercholesterolemia

Aim: to analyze adherence of FH patients with familial hypercholesterolemia (FH) to the statin therapy and reveal factors, which influence it; to assess the degree of target level of low-density lipoprotein cholesterol (LDLCH) achievement by FH patients on statin therapy. Materials and methods. We included in this study 203 FH patients aged >18 years (mean age 50.0±1.1 years, 82 men). Definite FH was diagnosed in 96 persons, in the other patients FH was considered possible. For evaluating the adherence to therapy with statins we used the Morisky-Green questionnaire. Results. Among patients with definite FH 57 % were adherent to lipid-lowering therapy, 16 % were partially adherent, and 27 % – not adherent. Target LDLCH levels were achieved in 22.6 % and 12.5 % of patients with definite and possible FH, respectively. Smoking and gender were not associated with adherence to statin therapy. Factors associated with higher adherence were age (p=0.000003), arterial hypertension (odds ratio [OR] 1.90, 95 % confidence interval [CI] 1.02 to 3.55], p=0.044), ischemic heart disease (IHD) (OR=2.99, 95 %CI 1.50 to 5.97, p=0.002), history of myocardial infarction (MI) (OR 5.26, 95 %CI 2.03 to 13.60, p=0.0006), history of myocardial revascularization (OR 20.3, 95 %CI 2.64 to 156.11, p=0.004) and the fact of achieving target LDLCH level (OR 19.93, 95 %CI 7.03 to 56.50, p<0.0001). The main reason for the refuse from statin therapy in 87 % of patients was fear of side effects. Main reasons for stopping of ongoing therapy were: myalgia, an increase in transaminases, skin rashes, and high cost in 12, 35, 12, and 6 % of patients, respectively. The decision to withdraw therapy with statins was made by 29 % of patients by themselves. Conclusion. In this study 57 % of patients with definite FH were adherent to statin therapy. Factors associated with increased adherence were age, hypertension, IHD, history of MI, history of myocardial revascularization, achievement of target LDLCH level. Target LDLCH levels were achieved by 22.6 and 12.5 %% of patients with definite and possible FH, respectively.

1. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register group. Atherosclerosis 1999;142:105–112.

2. Nordestgaard B.G., Chapman M.J., Humphries S.E. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34(45):3478–3490a.

3. Sijbrands E.J., Westendorp R.G., Paola Lombard M. et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolemia. Atherosclerosis 2000;149(2):421–425.

4. Karpov Ju.A., Bojcov S.A., Kuharchuk V.V. Consensus Statement of the Russian National Atherosclerosis Society (RNAS) Familial hypercholesterolemia in Russia: outstanding issues in diagnosis and management. Atherosclerosis and dyslipidemia 2015;2:5–16. Russian.

5. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 2010;24(1):19–28.

6. Smilde T.J., Wissen S., Wollersheim H. et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357(9256):577–581.

7. Huijgen R., Kindt I., Verhoeven S.B.J. et al. Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal. PLoS ONE 2010;5(2):e9220.

8. Huijgen R., Vissers M.N., Defesche J.C. et al.Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther 2008;6(4):567–581.

9. Versmissen J., Oosterveer D.M., Yazdanpanah M. et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.

10. Pijlman A.H., Huijgen R., Verhagen S.N. et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross — sectional study in The Netherlands. Atherosclerosis 2010;209:189–194.

11. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of self-reported measure of medical adherence. Med Care 1986;24(1):67–73.

12. Galema-Boers J.M., Lenzen M.J., van Domburg R.T. et al. Predicting non-adherence in patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2014;70(4):391–397.

13. Broekhuizen K., Jelsma J.G., van Poppel M.N. et al. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with familial hypercholesterolemia? BMC Public Health 2012;12:348.

14. Hollman G., Olsson A.G., Ek A.C. Disease knowledge and adherence to treatment in patients with familial hypercholesterolemia. J Cardiovasc Nurs 2006;21(2):103–108.

15. Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326(7404):1423

16. Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis 2014;24(10):1057–1066.

17. Banach M., Rizzo M., Toth P.P. et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Archives of Medical Science 2015;11(1):1–23.

18. Stroes E.S., Thompson P.D., Corsini A. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Atherosclerosis Society Consensus Panel. Eur Heart J 2015;36(17):1012–1022.

19. Perreault S., Dragomir A., Blais L. et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009;65(10):1013–1024.

20. Rasmussen J.N., Chong A., Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297(2):177–186.